2023
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyHormone-sensitive prostate cancerSensitive prostate cancerPositron emission tomographyConventional computerized tomographyDocetaxel chemotherapyClinical trialsProstate cancerCombination of ADTBackbone of treatmentCytoreductive radical prostatectomySequencing of therapyFirst-line treatmentEvaluation of patientsClinical practice guidelinesOngoing clinical trialsAndrogen receptor antagonistPubMed Medline databaseDeprivation therapyInitial managementOverall survivalStaging evaluationBone scanRandomized trials
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatients